JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease

Study Purpose

Background: Kohlmeier-Degos (K-D) is a rare disease that leads to the blockage of small blood vessels in many organs; these can include the skin, eyes, stomach, lungs, heart, and the brain and spinal cord (central nervous system, or CNS). There are no known effective treatments for K-D that affects the CNS. Objective: To test a drug (ruxolitinib) in a person with K-D affecting the CNS. Eligibility: This study is designed to treat 1 subject, a 58-year-old male with K-D affecting the CNS. Design: The participant will be screened: He will have a physical exam and blood tests. He will have skin biopsies: Small samples of skin will be removed. He will have a lumbar puncture: A needle will be inserted in his back to draw fluid from the space around the spinal cord. He will have a magnetic resonance imaging (MRI) scan: He will lie on a table that slides into a tube to take pictures of his brain and spinal cord. He will see a doctor who specializes in nerves. Ruxolitinib is a tablet taken by mouth. The participant will take the drug twice a day for up to 26 weeks. The dosage may change over time. The participant will have up to 7 clinic visits in 28 weeks. Each visit will be 1 to 3 days. MRI scans, biopsies, lumbar punctures, and other tests will be repeated on different visits. The participant may receive follow-up phone calls between visits. He will report any adverse effects. Unscheduled visits may be needed if new symptoms develop. The last follow-up will be 4 weeks after the last dose of the study drug....

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	No
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Interventional
Eligible Ages	18 Years and Over
Gender	All

More Inclusion & Exclusion Criteria

-
INCLUSION CRITERIA:
The study design was constructed to treat one subject, a 58 year old male with CNS Kohlmeier Degos Disease.

Therefore, there are no specific inclusion criteria.

EXCLUSION CRITERIA:

- Active life-threatening infections.

- Hemoglobin <7 g/dL.

- Platelet counts < 50 K /mcL.

- Neutropenia (ANC <0.5 x k/mcL) - Lymphopenia (ALC <0.2 x k/mcL) - LFTs (liver function test) > 3 x time upper limit.

- eGFR/CreatCr < 30 mL/min

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT05998395
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.	Phase 1/Phase 2
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	Cornelia D Cudrici, M.D.
Principal Investigator Affiliation	National Heart, Lung, and Blood Institute (NHLBI)
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	NIH
Overall Status	Recruiting
Countries	United States
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Kohlmeier Degos Disease With Neurologic Involvement
Study Website:	View Trial Website

Additional Details

Study Description: This single patient protocol will provide off-label treatment with a JAK/STAT ( Janus kinases/ Signal transducer and Activator of Transcription proteins) inhibitor to a patient with K(SqrRoot)(Delta)hlmeier Degos disease (K-D) with neurologic involvement. We hypothesize that ruxolitinib, which targets type I IFN (Interferons ) and IFN-y signaling, will attenuate various neurological manifestations of K-D that are observed clinically, radiologically or in abnormal laboratory findings in our K-D patient. This will help reduce IFN signaling in a manner that may slow or halt the disease progression as measured by the endpoints established below. Objectives: Primary Objective: To test the hypothesis that JAK/STAT inhibition by ruxolitinib will delay progression of neuroradiological manifestations of our one patient with neurological involvement of K-D disease. Exploratory Objectives: 1. Assess changes in immune cell proportion using single cell RNAseq (scRNA-seq) in biospecimens such as skin, cerebrospinal fluid (CSF) and blood after 13 weeks and up to 49 weeks of ruxolitinib treatment. 2. Assess changes in plasma/serum cytokines levels and IFN scores as well as biomarker assays in CSF/ blood samples after 13 weeks and up to 49 weeks of ruxolitinib treatment.. 3. To test the hypothesis that ruxolitinib will stabilize or improve clinical neurologic exams in this patient. Endpoints: Primary Endpoint: The primary endpoint is stability or regression of existing enhancing lesions or no development of new enhancing lesions in the brain and spine observed in MRI evaluation after 13 weeks and up to 49 weeks of ruloxitinib (10 mg BID) compared to pre-treatment MRI images. Exploratory endpoints of this study are clinical and potential surrogate biomarker efficacy data, including: 1. Changes in transcriptome/RNA expression determined by scRNA-seq in skin, CSF and peripheral blood mononuclear cells (PBMCs) between baseline measurements and after 13 weeks and up to 49 weeks of treatment. 2. Attenuation of plasma/serum cytokine levels and IFN scores as well as biomarker assays in CSF and blood samples between the baseline visit and after 13 weeks and up to 49 weeks of treatment. 3. Stability OR improvement of motor and/or sensory function on clinical neurologic exams between the baseline visit and after 13 weeks and up to 49 weeks of treatment.

Arms & Interventions

Arms

Experimental: Ruxolitinib

Ruxolitinib at 5 mg twice a day (BID) for 1 week and then at 10 mg BID for 13-24 weeks and 1 week of 5 mg BID before stopping ruxolitinib.

Interventions

Drug: - Ruxolitinib

Ruxolitinib at 5 mg twice a day (BID) for 1 week and then at 10 mg BID for 13-24 weeks and 1 week of 5 mg BID before stopping ruxolitinib.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Bethesda, Maryland

Status

Recruiting

Address

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892

Site Contact

NIH Clinical Center Office of Patient Recruitment (OPR)

[email protected]

800-411-1222 #TTY dial 711

Clinical Trial Finder